CBPO [China Biologic Products] SC 13D/A: (Original Filing)

[Execution Version CHINA BIOLOGIC PRODUCTS, INC. 2,775,000 SHARES OF COMMON STOCK (PAR VALUE $0.0001 PER SHARE) UNDERWRITING AGREEMENT June 2, 2016 June 2, 2016 Morgan Stanley & Co. International plc 25 Cabot Square, Canary Wharf London, E14 4QA United Kingdom Schedule I As the Sole Underwriter named in Ladies and Gentlemen: Selling Stockholders Company Schedule II Schedule I Underwriter Shares] [CUSIP No. 16938C106 1. Names of reporting persons. WP X Biologics LLC 2. Check the appropriate box if a member of a group (see instructions). ¨ x (a) 3. SEC use only 4. Source of funds (see instructions) N/A 5. ¨]

By | 2016-06-04T03:13:53+00:00 June 3rd, 2016|Categories: CBPO, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments
Read More

CBPO [China Biologic Products] SC 13D/A: Execution Version CHINA BIOLOGIC PRODUCTS, INC. 2,775,000 SHARES

[Execution Version CHINA BIOLOGIC PRODUCTS, INC. 2,775,000 SHARES OF COMMON STOCK (PAR VALUE $0.0001 PER SHARE) UNDERWRITING AGREEMENT June 2, 2016 June 2, 2016 Morgan Stanley & Co. International plc 25 Cabot Square, Canary Wharf London, E14 4QA United Kingdom Schedule I As the Sole Underwriter named in Ladies and Gentlemen: Selling Stockholders Company Schedule II Schedule I Underwriter Shares] [CUSIP No. 16938C106 1. Names of reporting persons. WP X Biologics LLC 2. Check the appropriate box if a member of a group (see instructions). ¨ x (a) 3. SEC use only 4. Source of funds (see instructions) N/A 5. ¨]

By | 2016-06-04T03:14:41+00:00 June 3rd, 2016|Categories: CBPO, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments
Read More

CBPO [China Biologic Products] 8-K: (Original Filing)

[FOR RELEASE May 4, 2016 China Biologic Reports Financial Results for the First Quarter of 2016 1Q16 Total Sales Up 29.4% with Non-GAAP Net Income Up 29.8% YoY in RMB terms, or Up 21.6% YoY to $85.6 Million and 21.6% YoY to $30.4 Million in USD terms, respectively BEIJING, China – May 4, 2016 – First Quarter 2016 Financial Highlights] [FORM 8-K CURRENT REPORT Date of Report (Date of Earliest event Reported): May 4, 2016 CHINA BIOLOGIC PRODUCTS, INC. Delaware 001-34566 75-2308816 (State or other jurisdiction of (Commission File No.) (IRS Employer ID No.) incorporation or organization) 18th Floor, Jialong International Building 19 Chaoyang Park Road Chaoyang District, Beijing 100125 People’s Republic of China 86-10-6598-3111 ____________________________________________________________ (Former name or former]

By | 2016-05-08T01:51:01+00:00 May 4th, 2016|Categories: CBPO, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments
Read More

CBPO [China Biologic Products] 8-K: FOR RELEASE May 4, 2016 China Biologic Reports

[FOR RELEASE May 4, 2016 China Biologic Reports Financial Results for the First Quarter of 2016 1Q16 Total Sales Up 29.4% with Non-GAAP Net Income Up 29.8% YoY in RMB terms, or Up 21.6% YoY to $85.6 Million and 21.6% YoY to $30.4 Million in USD terms, respectively BEIJING, China – May 4, 2016 – First Quarter 2016 Financial Highlights] [FORM 8-K CURRENT REPORT Date of Report (Date of Earliest event Reported): May 4, 2016 CHINA BIOLOGIC PRODUCTS, INC. Delaware 001-34566 75-2308816 (State or other jurisdiction of (Commission File No.) (IRS Employer ID No.) incorporation or organization) 18th Floor, Jialong International Building 19 Chaoyang Park Road Chaoyang District, Beijing 100125 People’s Republic of China 86-10-6598-3111 ____________________________________________________________ (Former name or former]

By | 2016-05-08T01:51:57+00:00 May 4th, 2016|Categories: CBPO, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments
Read More

CBPO [China Biologic Products] 10-Q: (Original Filing)

[] [CERTIFICATIONS I, David (Xiaoying) Gao, certify that: 1. I have reviewed this quarterly report on Form 10-Q of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [CERTIFICATIONS I, Ming Yang, certify that: 1. I have reviewed this quarterly report on Form 10-Q of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. th David (Xiaoying) Gao Chief Executive Officer] [2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. th Ming Yang Chief Financial Officer (Principal Financial Officer)]

By | 2016-05-08T01:53:13+00:00 May 4th, 2016|Categories: CBPO, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments
Read More

CBPO [China Biologic Products] 10-Q:

[] [CERTIFICATIONS I, David (Xiaoying) Gao, certify that: 1. I have reviewed this quarterly report on Form 10-Q of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [CERTIFICATIONS I, Ming Yang, certify that: 1. I have reviewed this quarterly report on Form 10-Q of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. th David (Xiaoying) Gao Chief Executive Officer] [2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. th Ming Yang Chief Financial Officer (Principal Financial Officer)]

By | 2016-05-08T01:54:05+00:00 May 4th, 2016|Categories: CBPO, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments
Read More

CBPO [China Biologic Products] IRANNOTICE: (Original Filing)

[China Biologic Products, Inc. 18th Floor, Jialong International Building 19 Chaoyang Park Road Chaoyang District, Beijing 100125 People’s Republic of China May 4, 2016 VIA EDGAR 100 F Street, N.E. Re: Notice of Disclosure Filed in Exchange Act Annual Report under Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the]

By | 2016-05-08T01:55:03+00:00 May 4th, 2016|Categories: CBPO, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments
Read More

CBPO [China Biologic Products] IRANNOTICE: China Biologic Products, Inc. 18th Floor, Jialong International

[China Biologic Products, Inc. 18th Floor, Jialong International Building 19 Chaoyang Park Road Chaoyang District, Beijing 100125 People’s Republic of China May 4, 2016 VIA EDGAR 100 F Street, N.E. Re: Notice of Disclosure Filed in Exchange Act Annual Report under Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the]

By | 2016-05-08T01:55:55+00:00 May 4th, 2016|Categories: CBPO, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments
Read More

CBPO [China Biologic Products] DEFA14A: SCHEDULE 14A x ¨ Check the appropriate box:

[SCHEDULE 14A x ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ ¨ Definitive Proxy Statement x Definitive Additional Materials ¨ Soliciting Material under Rule 14a-12 CHINA BIOLOGIC PRODUCTS, INC. ________________________________________________________ Payment of Filing Fee (Check the appropriate box): x No fee required ¨ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. (1) Title of]

By | 2016-05-08T01:57:59+00:00 April 29th, 2016|Categories: CBPO, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments
Read More
Skip to toolbar